Effectiveness of IκB kinase inhibitors in murine colitis-associated tumorigenesis

Journal of Gastroenterology

Volumn 44, Issue 9, 2009, Pages 935-943

  Hayakawa, Yoku ^a   Maeda, Shin ^a,b   Nakagawa, Hayato ^a   Hikiba, Yohko ^b   Shibata, Wataru ^a   Sakamoto, Kei ^b   Yanai, Ayako ^b   Hirata, Yoshihiro ^a   Ogura, Keiji ^a   Muto, Susumu ^c   Itai, Akiko ^c   Omata, Masao ^a  

^a UNIVERSITY OF TOKYO   (Japan)

^b INSTITUTE FOR ADULT DISEASES   (Japan)

^c Inst of Medicinal Molecular Design   (Japan)

Author keywords

Cytokine; Inflammatory bowel disease (IBD); NF B; Tumor

Indexed keywords

AZOXYMETHANE; CYCLOOXYGENASE 2; DEXTRAN SULFATE; I KAPPA B ALPHA; I KAPPA B KINASE; I KAPPA B KINASE INHIBITOR; IMD 0354; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERLEUKIN 1BETA; INTERLEUKIN 6; NEMO BINDING DOMAIN PEPTIDE; SYNAPTOTAGMIN I; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG; ANTINEOPLASTIC AGENT; BENZAMIDE DERIVATIVE; N (3,5 BIS(TRIFLUOROMETHYL)PHENYL) 5 CHLORO 2 HYDROXYBENZAMIDE; N-(3,5-BIS(TRIFLUOROMETHYL)PHENYL)-5-CHLORO-2-HYDROXYBENZAMIDE; NBD PEPTIDE, MOUSE; PEPTIDE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER INHIBITION; CANCER PREVENTION; CELL PROLIFERATION; COLITIS; COLON CARCINOGENESIS; COLON MUCOSA; COLORECTAL CANCER; CONTROLLED STUDY; ENZYME ACTIVATION; ENZYME DEGRADATION; ENZYME INHIBITION; ENZYME PHOSPHORYLATION; IMMUNOHISTOCHEMISTRY; MACROPHAGE; MALE; MOUSE; NEUTROPHIL CHEMOTAXIS; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; TUMOR LOCALIZATION; TUMOR VOLUME; ANIMAL; C57BL MOUSE; COLORECTAL TUMOR; DRUG ANTAGONISM; DRUG DELIVERY SYSTEM; DRUG EFFECT; DRUG SCREENING; METABOLISM; PATHOLOGY; PATHOPHYSIOLOGY;

ANIMALS; ANTINEOPLASTIC AGENTS; AZOXYMETHANE; BENZAMIDES; CELL PROLIFERATION; COLITIS; COLORECTAL NEOPLASMS; DEXTRAN SULFATE; DRUG DELIVERY SYSTEMS; DRUG SCREENING ASSAYS, ANTITUMOR; I-KAPPA B KINASE; MACROPHAGES; MALE; MICE; MICE, INBRED C57BL; NEUTROPHIL INFILTRATION; NF-KAPPA B; PEPTIDES;

EID: 70349652354     PISSN: 09441174     EISSN: 14355922     Source Type: Journal    
DOI: 10.1007/s00535-009-0098-7     Document Type: Article

References (23)

1. Fiocchi C. Inflammatory bowel disease: Etiology and pathogenesis. Gastroenterology. 1998;115:182-205.
2. Eaden JA, Abrams KR, Mayberry JF. The risk of colorectal cancer in ulcerative colitis: A meta-analysis. Gut. 2001;48:526-35.
3. Higaki S, Akazawa A, Nakamura H, Yanai H, Yoshida T, Okita K. Metaplastic polyp of the colon develops in response to inflammation. J Gastroenterol Hepatol. 1999;14:709-14.
4. Coussens LM, Werb Z. Inflammation and cancer. Nature. 2002;420:860-7.
5. Seril DN, Liao J, Yang GY, Yang CS. Oxidative stress and ulcerative colitis-associated carcinogenesis: Studies in humans and animal models. Carcinogenesis. 2003;24:353-62.
6. Thun MJ, Namboodiri MM, Heath CW Jr. Aspirin use and reduced risk of fatal colon cancer. N Engl J Med. 1991;325:1593-6.
7. Kohno H, Suzuki R, Sugie S, Tanaka T. Suppression of colitis-related mouse colon carcinogenesis by a COX-2 inhibitor and PPAR ligands. BMC cancer. 2005;5:46.
8. Karin M, Cao Y, Greten FR, Li ZW. NF-kappaB in cancer: From innocent bystander to major culprit. Nat Rev Cancer. 2002;2:301-10.
9. Hacker H, Karin M. Regulation and function of IKK and IKK-related kinases. Sci STKE. 2006;2006:rE13.
10. Shibata W, Maeda S, Hikiba Y, et al. Cutting edge: The I{kappa}B kinase (IKK) inhibitor, NEMO-binding domain peptide, blocks inflammatory injury in murine colitis. J Immunol. 2007;179:2681-5.
11. Greten FR, Eckmann L, Greten TF, et al. IKKbeta links inflammation and tumorigenesis in a mouse model of colitis-associated cancer. Cell. 2004;118:285-96.
12. Pikarsky E, Porat RM, Stein I, et al. NF-kappaB functions as a tumour promoter in inflammation-associated cancer. Nature. 2004;431:461-6.
13. Becker C, Fantini MC, Schramm C, et al. TGF-beta suppresses tumor progression in colon cancer by inhibition of IL-6 trans-signaling. Immunity. 2004;21:491-501.
14. May MJ, D'Acquisto F, Madge LA, Glockner J, Pober JS, Ghosh S. Selective inhibition of NF-kappaB activation by a peptide that blocks the interaction of NEMO with the IkappaB kinase complex. Science. 2000;289:1550-4.
15. Onai Y, Suzuki J, Kakuta T, et al. Inhibition of IkappaB phosphorylation in cardiomyocytes attenuates myocardial ischemia/reperfusion injury. Cardiovasc Res. 2004;63:51-9.
16. Tanaka A, Konno M, Muto S, et al. A novel NF-kappaB inhibitor, IMD-0354, suppresses neoplastic proliferation of human mast cells with constitutively activated c-kit receptors. Blood. 2005;105:2324-31.
17. Tanaka A, Muto S, Konno M, Itai A, Matsuda H. A new IkappaB kinase beta inhibitor prevents human breast cancer progression through negative regulation of cell cycle transition. Cancer Res. 2006;66:419-26.
18. Yanai A, Maeda S, Shibata W, et al. Activation of IkappaB kinase and NF-kappaB is essential for Helicobacter pylori -induced chronic gastritis in Mongolian gerbils. Infect Immun. 2008;76:781-7.
19. Maeda S, Hsu LC, Liu H, et al. Nod2 mutation in Crohn's disease potentiates NF-kappaB activity and IL-1beta processing. Science. 2005;307:734-8.
20. Greten FR, Karin M. The IKK/NF-kappaB activation pathway-a target for prevention and treatment of cancer. Cancer Lett. 2004;206:193-9.
21. Hanauer SB, Feagan BG, Lichtenstein GR, et al. Maintenance infliximab for Crohn's disease: The ACCENT I randomised trial. Lancet. 2002;359:1541-9.
22. Sands BE, Anderson FH, Bernstein CN, et al. Infliximab maintenance therapy for fistulizing Crohn's disease. N Engl J Med. 2004;350:876-85.
23. Popivanova BK, Kitamura K, Wu Y, et al. Blocking TNF-alpha in mice reduces colorectal carcinogenesis associated with chronic colitis. J Clin Invest. 2008;118:560-70.